Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To provide fully integrated services in the areas of DMPK, pharmacology and toxicology for Elara's oncology programs
Subscribe to our email newsletter
Shanghai ChemPartner (ChemPartner), a wholly-owned subsidiary of ShangPharma, has extended its drug discovery collaboration with Elara.
ChemPartner will provide fully integrated services in the areas of DMPK, pharmacology and toxicology for Elara’s lead oncology programs. Members of the joint project team from both sides will work together to design and execute a drug screening cascade.
Joe Lewis, CEO and founder of Elara, said: This new relationship is a natural result of the services provided by ChemPartner. The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.
Our new integrated relationship will enable Elara to further leverage ChemPartner’s strong R&D capabilities from discovery to early development phase. We anticipate a stronger strategic partnership down the road as our program progresses, he added.